A5038211013- Monoclonal and Polyclonal Antibodies Research
- Radiopharmaceutical Chemistry and Applications
- Advanced Biosensing Techniques and Applications
- Biosimilars and Bioanalytical Methods
- Synthesis and Biological Evaluation
- CAR-T cell therapy research
- Nanofabrication and Lithography Techniques
- Brucella: diagnosis, epidemiology, treatment
- T-cell and B-cell Immunology
- Clinical Laboratory Practices and Quality Control
- Alzheimer's disease research and treatments
- Protein purification and stability
- Statistical Methods in Clinical Trials
- Immune Cell Function and Interaction
- Pharmacogenetics and Drug Metabolism
- Immunotherapy and Immune Responses
- Neuroinflammation and Neurodegeneration Mechanisms
- Chemokine receptors and signaling
- Cell Adhesion Molecules Research
- Pharmaceutical studies and practices
- Inhalation and Respiratory Drug Delivery
- Prion Diseases and Protein Misfolding
- Cholesterol and Lipid Metabolism
- Bacillus and Francisella bacterial research
- Burkholderia infections and melioidosis
UCB Pharma (United Kingdom)
2017-2023
Roche (Switzerland)
2013-2022
La Roche College
2022
Novartis (Switzerland)
2012-2014
Novartis Institutes for BioMedical Research
2013-2014
Bioanalytica (Switzerland)
2014
Centre National de la Recherche Scientifique
2008-2009
Université de Montpellier
2003-2009
Centre d’études d’agents Pathogènes et Biotechnologies Pour la Santé
2008-2009
Inserm
2003-2006
CEA TCB is a novel IgG-based T-cell bispecific (TCB) antibody for the treatment of CEA-expressing solid tumors currently in phase I clinical trials (NCT02324257). Its format incorporates bivalent binding to CEA, head-to-tail fusion CEA- and CD3e-binding Fab domains an engineered Fc region with completely abolished FcγRs C1q. The study provides mechanistic insights into activity mode action TCB.CEA was characterized on 110 cell lines vitro xenograft tumor models vivo using NOG mice engrafted...
Over 400 professionals representing pharmaceutical companies, CROs, and multiple regulatory agencies participated in the 6th Workshop on Recent Issues Bioanalysis (WRIB). Like previous sessions, this event was format of a practical, focused, highly interactive informative workshop aiming for high-quality, improved compliance scientific excellence. Numerous 'hot' topics bioanalysis both small large molecules were shared discussed, leading to consensus recommendations among panelists attendees...
The 2013 7th Workshop on Recent Issues in Bioanalysis was held Long Beach, California, USA, where close to 500 professionals from pharmaceutical and biopharmaceutical companies, CROs regulatory agencies convened discuss current topics of interest bioanalysis. These 'hot' topics, which covered both small large molecules, were the starting point for fruitful exchanges knowledge, sharing ideas among speakers, panelists attendees. discussions led specific recommendations pertinent bioanalytical...
CEA TCB is a novel T-cell-bispecific (TCB) antibody targeting the carcinoembryonic antigen (CEA) expressed on tumor cells and CD3 epsilon chain (CD3e) present T cells, which currently in Phase 1 clinical trials (NCT02324257) for treatment of CEA-positive solid tumors. Because human (hCEA) binder does not cross-react with cynomolgus monkey absent rodents, alternative nonclinical safety evaluation approaches were considered. These included development cross-reactive homologous (surrogate)...
Various approaches to first-in-human (FIH) starting dose selection for new molecular entities (NMEs) are designed minimize risk trial subjects. One approach uses the minimum anticipated biological effect level (MABEL), which is a conservative method intended maximize subject safety and primarily NMEs having high perceived risks. However, there concern that MABEL being inappropriately used lower molecules with negative impacts on drug development time patient access. In addition, ambiguity...
Abstract Human Vγ9Vδ2 T cells play a crucial role in early immune response to intracellular pathogens. Moreover, brucellosis, these are drastically increased the peripheral blood of patients during acute phase infection. In vitro, capable inhibiting Brucella growth and development through combination mechanisms: 1) cytotoxicity, 2) macrophage activation bactericidal activity cytokine chemokine secretion, 3) antibacterial effects. We previously described that factors were found supernatants...
NKT cells belong to a conserved T lymphocyte subgroup that has been implicated in the regulation of various immune responses, including responses viruses, bacteria, and parasites. They express semi-invariant TCR recognizes glycolipids presented by nonpolymorphic MHC class I-like molecule CD1d, upon activation, they produce pro- anti-inflammatory cytokines. Recent studies have shed light on nature environmental signals may influence production cytokines thus, modulate response. To better...
Background: The fully human monoclonal antibody mAb123, which binds to and neutralizes chemokine motif ligand-21 (CCL21) displays a faster clearance in cynomolgus monkey compared with typical IgG kinetics. A direct an immunoaffinity LC–MS/MS assays were developed compare the previously established ligand-binding (LBAs). Results: strong correlation of pharmacokinetic data LBA confirmed rapid drug disposition mAb123 is intrinsic property molecule, rather than interference anti-mAb123...
Monoclonal antibodies (mAbs) are a rapidly growing drug class for which great efforts have been made to optimize certain molecular features achieve the desired pharmacokinetic (PK) properties. One approach is engineer interactions of mAb with neonatal Fc receptor (FcRn) by introducing specific amino acid sequence mutations, and assess their effect on PK profile in vivo studies. Indeed, FcRn protects mAbs from intracellular degradation, thereby prolongs antibody circulation time plasma...
Abstract Human Vγ9Vδ2 T cells pay a crucial role in early immune response to intracellular pathogens. In brucellosis infection, this population of is drastically increased the peripheral blood patients during acute phase infection. vitro, exhibit strong cytolytic activity against Brucella-infected and are able impair growth Brucella suis autologous macrophages. study, we have investigated relative importance contact-dependent mechanisms versus soluble factors viability B. suis. We show that...
Alzheimer's disease (AD) is a complex disorder for which various in vivo models exist. The TgCRND8 mouse, transgenic the human amyloid precursor protein, an aggressive early onset model of brain deposition. Preliminary studies revealed that when transgene expressed on A/J genetic background, these mice not only survive longer but also deposit less parenchymal amyloid-β (Aβ) peptides as compared to those C57BL/6 background. We performed genome-wide study F2 intercross between background and...
Human invariant NKT (iNKT) cells are a unique subset of T cells, which recognize glycolipids presented by the CD1d. Among iNKT several functionally distinct subsets have been characterized according to CD4 and/or CD8 co-receptor expression. The current study is focussed on CD4(+) cell and its role in an anti-infectious response. We examined intracellular Brucella suis growth. Our results indicate that impair intramacrophagic growth Brucella. This inhibition due combination soluble...
QBP359 is an IgG1 human monoclonal antibody that binds with high affinity to CCL21, a chemokine hypothesized play role in inflammatory disease conditions through activation of resident CCR7-expressing fibroblasts/myofibroblasts. The pharmacokinetics (PK) and pharmacodynamics (PD) non-human primates were characterized integrated approach, combining PK, PD, immunogenicity, immunohistochemistry (IHC) tissue profiling data from single- multiple-dose experiments cynomolgus monkeys. When compared...
Abstract The global immune response can be simplified into two components: the innate and acquired systems. comprises primarily macrophages NK cells, while B T cells orchestrate response. Human Vγ9Vδ2 represent a minor cell subpopulation in blood (1–5%) that is activated via TCR by small nonpeptidic molecules. Their percentage dramatically increases during early phase of infection intracellular pathogens, they display many characteristics which places them at unique position within system....
The bioanalytical scientist plays a key role in the project team for drug development of biotherapeutics from discovery to marketing phase. Information members is required assay and sample analysis during discovery, preclinical clinical phases input needed help data interpretation. European Bioanalysis Forum target 20 discussed many gaps information communication between as base providing perspective on scientist's interactions within team.
Abstract T cell bispecific antibodies that recruit and engage cells for tumor killing through binding to the receptor (TCR) upon a antigen (TA) subsequent crosslinking have attracted broad interest. Here, we describe novel asymmetric head-to-tail 2+1 antibody (2+1 TCB) platform characterized by fusion of flexible Fab fragment N-terminus CD3e heterodimeric TA-CD3e IgG1 in geometry via linker. The resulting TCB is monovalent (KD 70-100 nM) binds bivalently with avidity TA on target cell....